Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease - Goto, S; Ogawa, H; Takeuchi, M (Eur Heart J, 2010)
et al.